Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

miR-29ab1 Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis.
[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis.
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial.
Copaiba Oil Suppresses Inflammatory Cytokines in Splenocytes of C57Bl/6 Mice Induced with Experimental Autoimmune Encephalomyelitis (EAE).
Acute disseminated encephalomyelitis in Siriraj Hospital: clinical manifestations and short-term outcome.
The grey matter correlates of impaired decision-making in multiple sclerosis.
Chronic pain following spinal cord injury.
Neuroscience. To learn is to myelinate.
Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential.
Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design.
Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial.
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.
Minocycline Hydrochloride (1818)
The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a new class of nanomolar FKBP12 ligands.
Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis.
Vitamin D in health and disease: a literature review.
Genetic control of nerve conduction velocity may influence multiple sclerosis phenotype.
JCV granule cell neuronopathy and GCN-IRIS under natalizumab treatment.
Self-efficacy and health status improve after a wellness program in persons with multiple sclerosis.
Cell-based therapy approaches: the hope for incurable diseases.
Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis.

Pages